Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30614795)

  • 1. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
    Li H; Wang H; Deng K; Han W; Hong B; Lin W
    Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.
    Tahir SK; Wass J; Joseph MK; Devanarayan V; Hessler P; Zhang H; Elmore SW; Kroeger PE; Tse C; Rosenberg SH; Anderson MG
    Mol Cancer Ther; 2010 Mar; 9(3):545-57. PubMed ID: 20179162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
    Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H
    Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
    Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
    Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
    [No Abstract]   [Full Text] [Related]  

  • 7. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
    Kim EY; Jung JY; Kim A; Chang YS; Kim SK
    Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
    Hann CL; Daniel VC; Sugar EA; Dobromilskaya I; Murphy SC; Cope L; Lin X; Hierman JS; Wilburn DL; Watkins DN; Rudin CM
    Cancer Res; 2008 Apr; 68(7):2321-8. PubMed ID: 18381439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
    Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.
    Greenberg EF; McColl KS; Zhong F; Wildey G; Dowlati A; Distelhorst CW
    Cell Death Dis; 2015 Dec; 6(12):e2034. PubMed ID: 26720343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X
    Inoue-Yamauchi A; Oda H
    Biochem Biophys Res Commun; 2020 Jun; 526(3):612-617. PubMed ID: 32247610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.
    Lam LT; Lin X; Faivre EJ; Yang Z; Huang X; Wilcox DM; Bellin RJ; Jin S; Tahir SK; Mitten M; Magoc T; Bhathena A; Kati WM; Albert DH; Shen Y; Uziel T
    Mol Cancer Ther; 2017 Aug; 16(8):1511-1520. PubMed ID: 28468776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.
    Loriot Y; Mordant P; Dugue D; Geneste O; Gombos A; Opolon P; Guegan J; Perfettini JL; Pierre A; Berthier LK; Kroemer G; Soria JC; Depil S; Deutsch E
    Cell Death Dis; 2014 Sep; 5(9):e1423. PubMed ID: 25232677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells.
    Ohgino K; Terai H; Yasuda H; Nukaga S; Hamamoto J; Tani T; Kuroda A; Arai D; Ishioka K; Masuzawa K; Ikemura S; Kawada I; Naoki K; Fukunaga K; Soejima K
    Cancer Sci; 2020 Oct; 111(10):3793-3801. PubMed ID: 32687646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
    Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
    Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
    Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.